5E3 specifically recognizes synthetic Aβ oligomers, not monomers, fibrils or insoluble plaque.

Description

More than a decade of investigation has implicated oligomers of the amyloid-β (Aβ) peptide as the primary toxic species responsible for synaptotoxicity and neurodegeneration associated with Alzheimer’s disease.

Aptevo Therapeutics is the exclusive licensee of technology to develop novel immunotherapeutics to treat Alzheimer’s disease. This technology includes a highly selective humanized monoclonal antibody, 5E3, and a unique oligomer Aβ mimic for vaccine/diagnostic applications.

One of the key differentiating factors of the 5E3 monoclonal antibody is the selectivity for the toxic oligomers of Aβ, sparing the normal amyloid forms (full-length amyloid precursor protein (APP) and monomers) and insoluble plaque.

Significant non-dilutive funding has been awarded to this program through Brain Research Canada and Canadian Institute of Health Research to advance the 5E3/cSNK technologies in collaboration with the licensor of this technology, Dr. Neil Cashman, the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases and neurologist-neuroscientist at the University of British Columbia.

5E3 specifically recognizes synthetic Aβ oligomers, not monomers, fibrils or insoluble plaque.